Send us a text

🧠 Hidden epidemic:

50–70% of premenopausal women have iron deficiency.

Also common in CKD, GI bleeding, chronic disease.

🔍 Diagnosis Pearls:

Ferritin cutoff: <30 ng/mL (not 20!) for iron deficiency.

RLS patients: target ferritin >75.

Consider retic count: low = underproduction; high = bleeding/hemolysis.

💊 Treatment Tips:

Oral iron: ferrous sulfate preferred; daily dosing > TID.

Take with meat or vitamin C, avoid calcium or tea.

Alternate-day dosing may reduce GI side effects (but tricky compliance).

IV iron if oral not tolerated or patient is inflamed.

🧩 Clinical Takeaway:

Check for functional iron deficiency in inflammatory states.

Choose IV formulations based on cost, availability, and dosing frequency.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 HFrEF treatment = a race against time.

Goal: Start all 4 pillars of therapy within 6 weeks of discharge.

🎯 The Fantastic Four:

ACEI/ARB/ARNI (ARNI preferred).

Beta-blocker (Metoprolol succinate, Carvedilol, Bisoprolol).

MRA (Spironolactone, Eplerenone).

SGLT2i (Dapagliflozin, Empagliflozin).

🧪 STRONG-HF Trial:

Rapid uptitration significantly ↓ readmissions and death.

⚠️ Barriers:

Cost: ARNI & SGLT2i.

Tolerability: hypotension, renal function, hyperkalemia.

🧩 Clinical Takeaway:

Start all 4 classes early, even at low doses.

You can titrate up later — initiation > optimization.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Background:

RSV causes significant morbidity/mortality in older adults.

Previously considered a pediatric virus only.

📈 Epidemiology:

Hospitalization rate:

91/100,000 (ages 64–74).

738/100,000 in assisted living patients.

💉 Vaccine Update:

CDC now recommends RSV vaccine for:

All ≥75 years old.

60–74 years with chronic conditions (lung, kidney, diabetes with organ damage).

Efficacy: 71–80%, wanes to ~50% by 19 months.

⚠️ Considerations:

Possible risk of Guillain-Barré — ongoing surveillance.

Only one dose needed (no boost from second shot yet).

🧩 Clinical Takeaway:

Strongly recommend for frail seniors and those in communal living.

Shared decision-making still advised for those age 60–74.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Context:

Rising rates of carbapenem-resistant gram-negatives, especially those producing MBLs like NDM, VIM.

💊 Drug Combo:

Aztreonam + Avibactam = a lifeline for metallo-beta-lactamase (MBL) producers.

FDA-approved for:

Complicated intra-abdominal infections (with metronidazole).

Hospital-acquired and ventilator-associated pneumonias (HAP/VAP).

🧩 Clinical Takeaway:

Reserved for pan-resistant infections; not a first-line agent.

ID consult required in most hospitals due to high cost and restricted use.

This is your last-resort ammo — know when to reach for it.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Core Concept:

Cerebral perfusion pressure (CPP) = MAP – ICP.

Normal ICP = ~10 mmHg; threshold for concern >20 mmHg.

🧰 Management Strategies:

Elevate head of bed (30°), ensure neck is midline.

3% hypertonic saline preferred over mannitol in AKI.

Short-term hyperventilation (↓ PaCO₂ → vasoconstriction).

Consider sedation or decompressive craniectomy in refractory cases.

External ventricular drain (EVD) for CSF removal and monitoring.

🧩 Clinical Takeaway:

Managing ICP is about protecting perfusion.

Monitor trends closely — especially in trauma, hemorrhage, hepatic encephalopathy.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Problem:

80% of menopausal women suffer from vasomotor symptoms (hot flashes, night sweats).

Many can't take hormone therapy (VTE, CAD, breast CA).

💊 Fezolinetant:

NK3 receptor antagonist — first in class.

Reduces frequency and intensity of hot flashes.

Safe in patients who can’t take estrogen.

⚠️ Side Effects:

GI symptoms, transaminitis.

Requires liver function monitoring.

🧩 Clinical Takeaway:

A breakthrough for non-hormonal menopause management.

Ideal for patients at high risk or contraindications to HRT.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Historical practice:

Pre-load clopidogrel (or ticagrelor) before cath.

Rationale: reduce thrombotic burden prior to PCI.

🧪 New Data:

Large observational study: 100k+ NSTEMI patients.

No benefit in MI or death with pretreatment.

Longer LOS, delayed CABG in pre-treated patients.

🧩 Clinical Takeaway:

Defer P2Y12 until coronary anatomy is known — especially if CABG is on the table.

If PCI is clearly planned and delay expected — preloading may still be reasonable.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Surprising contender:

OA is not just wear-and-tear — there's an inflammatory phenotype.

🧪 Trial:

MTX 10–25 mg/week in knee OA with persistent pain.

Significant ↓ pain and improved function vs placebo.

⚠️ Side Effects:

GI upset, mouth ulcers, fatigue.

Hepatotoxicity, myelosuppression, pulmonary fibrosis (rare).

Always co-prescribe folic acid.

🧩 Clinical Takeaway:

Consider in refractory OA when NSAIDs, injections, and PT have failed.

Especially useful when opioids are not an option.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧪 The EPOC Trial:

Compared FLOT chemotherapy alone vs chemo + radiation before surgery in localized esophageal/gastroesophageal adenocarcinoma.

📈 Findings:

FLOT alone led to better 3-year progression-free survival: 51.6% vs 35%.

No survival benefit from adding radiation.

Patients receiving FLOT alone had fewer complications, improved tolerance, and less treatment-related morbidity.

🧩 Clinical Takeaway:

For operable esophageal adenocarcinoma, skip the radiation if you're doing full-dose chemo.

Less burden for patients, especially elderly or frail.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

📊 What It Is:

A modern CV risk estimator developed from 2.3 million-person dataset.

Replaces outdated ASCVD calculator (based on 25k).

🧠 Features:

Adds BMI, GFR, A1C, and zip code.

Omits race — more equitable.

Outputs risk of heart disease, stroke, heart failure.

⚠️ Caveats:

Generally gives lower risk estimates vs ASCVD.

May reduce statin overuse, but some feel it's too conservative.

🧩 Clinical Takeaway:

Helpful in primary prevention — especially borderline cases.

Use side-by-side with ASCVD for now until guidelines update.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.